Tertiary hyperparathyroidism is a state of excessive secretion of parathyroid hormone (PTH) after a long period of secondary hyperparathyroidism and resultinghypercalcemia. It reflects development of autonomous (unregulated) parathyroid function following a period of persistent parathyroid stimulation.
The basis of treatment is still prevention in chronic renal failure, starting medication and dietary restrictions long before dialysis treatment is initiated. Cinacalcet has greatly reduced the number of patients who ultimately require surgery for secondary hyperparathyroidism; however, approximately 5% of patients do not respond to medical therapy.
When secondary hyperparathyroidism is no longer responsive to treatment by medication, it is called tertiary hyperparathyroidism. The treatment of choice is surgical removal of three and one half parathyroid glands.
Secondary hyperparathyroidism refers to the excessive secretion of parathyroid hormone (PTH) by the parathyroid glands in response to hypocalcemia (low bloodcalcium levels) and associated hypertrophy of the glands. This disorder is especially seen in patients with chronic renal failure.
=====================================
59 承上題,患者接受副甲狀腺切除手術。下列術前抽血檢查項目中,何者最能預測術後併發低血鈣血症?
鈣離子(calcium ion)濃度磷酸根離子(phosphate ion)濃度
鎂離子(magnesium ion)濃度鹼性磷酸酶(alkaline phosphatase, ALP)濃度
How is it used?
Any condition that affects bone growth or causes increased activity of bone cells can affect ALP levels in the blood. An ALP test may be used, for example, to detect cancers that have spread to the bone or to help diagnose Paget's disease. This test may also sometimes be used to monitor treatment of Paget's disease or other bone conditions, such as vitamin D deficiency.
No comments:
Post a Comment